Parsing the thyroid cytopathology suspicious for malignancy diagnosis through molecular‐derived risk of malignancy and other related parameters: Insights into nodule characteristics and practice patterns

IntroductionThyroid cytopathology cases with suspicious for malignancy (SFM) diagnosis often result in resection. However, molecular testing offers details that may provide additional insights. In this study, the molecular profiles of SFM cases from two institutions that routinely used ThyroSeq v3 (TSV3) were examined.Materials and MethodsFollowing institutional review board approval, SFM thyroid cytopathology cases with TSV3 results were retrieved from the databases of two institutions. Molecular information including molecular‐derived risk of malignancy (MDROM), cytologic‐histologic correlation data, and other related parameters were calculated. Statistical comparisons were made with a p <.05 considered significant.ResultsThe core data set comprised 114 SFM cases that passed TSV3 quality assurance. All TSV3 results were reported as positive or negative for genomic alterations and all except five cases provided a probability of malignancy estimate. The overall combined baseline MDROM of 75.7% (95% CI, 70.0–81.4) was comparable to the risk of malignancy (74%) published in the Bethesda System. There was a statistically significant difference between the combined MDROMs of resected and unresected cohorts (79.0% vs 58.6%; p = .0153). Interestingly, the MDROMs of the resected cohorts from the two institutions were statistically different (75.0% vs 85.3%; p = .020). Cytologic–histologic correlation revealed malignant outcome in 88.5% of resected cases.ConclusionsMolecular analyses of SFM cases demonstrated higher risk genomic alterations that were associated with histologically overt neoplasms, resulting in increased malignancy outcome compared to baseline. MDROM analysis revealed differences in the cytopathologic practice patterns regarding follicular‐patterned neoplasms at the two institutions.